Trial Profile

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) in Patients With Recurrent/Refractory Malignant Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tifcemalimab (Primary) ; Toripalimab (Primary)
Indications Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Shanghai Junshi Biosciences

Most Recent Events

15 May 2024 Status changed from active, no longer recruiting to completed.
12 Dec 2023 Results(n=71, cutoff date of July 19, 2023, median age 38 (range 19-70) years) assessing safety, pharmacokinetics, and efficacy, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
27 Jul 2023 Planned End Date changed from 15 Jun 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com